
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$167.22
−US$7.64 · -4.37%
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
前收盤價
US$167.22
−US$7.64 · -4.37%
盤前
US$164
−US$3.22 · -1.93%
10月8日 上午9:08 ET
盤中時間採用ET。市場資料可能有所延遲。
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$167.22
52週區間
目前US$167.22
盤中時間採用ET。市場資料可能有所延遲。
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$167.22
52週區間
目前US$167.22
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.38億 USD | 6.34億 USD | 6.32億 USD | 8.02億 USD | 6.71億 USD |
| 銷貨成本 | 3.91億 USD | 3.6億 USD | 3.54億 USD | 3.46億 USD | 2.79億 USD |
| 毛利 | 3.48億 USD | 2.75億 USD | 2.78億 USD | 4.56億 USD | 3.91億 USD |
| 研究與開發 | 5417.7萬 USD | 4320萬 USD | 4272.2萬 USD | 4393.6萬 USD | 3427.4萬 USD |
| 銷售、一般及管理費用 | 2.91億 USD | 2.63億 USD | 2.19億 USD | 2.16億 USD | 1.84億 USD |
| 營業費用 | 2.88億 USD | 3.1億 USD | 2.31億 USD | 2.31億 USD | 2.24億 USD |
| 利息收入 | 2757.4萬 USD | — | — | 697.8萬 USD | 17.6萬 USD |
| 利息支出 | 2317.3萬 USD | 2257.4萬 USD | 1002.6萬 USD | 297.7萬 USD | 1271.4萬 USD |
| 折舊和攤銷 | 9695.6萬 USD | 8656.2萬 USD | 8611.4萬 USD | 5701.2萬 USD | 3844.7萬 USD |
| 營業利益 | 5957.8萬 USD | −3511.4萬 USD | 4770.3萬 USD | 2.25億 USD | 1.67億 USD |
| 淨利 | 4889.4萬 USD | −2551.4萬 USD | 3559.6萬 USD | 1.86億 USD | 1.28億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$173.86
上漲空間 3.97%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.08億0.01%2.3兆 USD0.03%US$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB2.23億0.12%1853億 USD0.03%US$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK1.28億0.28%447億 USD0.05%US$342.24-1.50%
Vanguard Extended Market ETFVXF1.12億0.11%954億 USD0.05%US$233.49-1.56%
First Trust NYSE Arca Biotechnology Index FundFBT1.1億3.80%28.89億 USD0.55%US$263.49-0.56%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY7307.54萬0.28%259.8億 USD0.23%US$663.94-1.64%
iShares Biotechnology ETFIBB7050.43萬0.68%104.01億 USD0.44%US$203.34+0.12%
Dimensional - US Small Cap ETFDFAS6931.43萬0.20%336.6億 USD0.31%US$77.92-1.38%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
First Trust NYSE Arca Biotechnology Index FundFBT
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares Biotechnology ETFIBB
Dimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。